60 related articles for article (PubMed ID: 9866990)
1. [Clearance of gadolinium contrast agent by hemodialysis: in vitro and clinical studies].
Katagiri K; Okada S; Kumazaki T; Tsuboi N
Nihon Igaku Hoshasen Gakkai Zasshi; 1998 Nov; 58(13):739-44. PubMed ID: 9866990
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetics of gadolinium-DTPA in chronic renal insufficiency requiring dialysis].
Krahe T; Götz R; Lackner K; Haustein J; Klemenz U; Landwehr P; Heidbreder E; Schuhmann-Giampieri G
Rofo; 1992 Jun; 156(6):523-6. PubMed ID: 1617171
[TBL] [Abstract][Full Text] [Related]
4. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of excess gadolinium into human bone from medical contrast agents.
Darrah TH; Prutsman-Pfeiffer JJ; Poreda RJ; Ellen Campbell M; Hauschka PV; Hannigan RE
Metallomics; 2009 Nov; 1(6):479-88. PubMed ID: 21305156
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the elimination and safety of gadodiamide injection in patients with hemodialysis].
Abe M; Kuno T; Takahashi Y; Nagura Y; Matsumoto K
Nihon Jinzo Gakkai Shi; 2004; 46(8):810-4. PubMed ID: 15645738
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein levels and clinical symptoms following gadolinium administration in hemodialysis patients.
Schieren G; Tokmak F; Lefringhausen L; van Bracht M; Perings C; Willers R; Günsel A; Kemper F; Wiesmüller GA; Rump LC
Am J Kidney Dis; 2008 Jun; 51(6):976-86. PubMed ID: 18501785
[TBL] [Abstract][Full Text] [Related]
8. Clearance of gadolinium chelates by hemodialysis: an in vitro study.
Choyke PL; Girton ME; Vaughan EM; Frank JA; Austin HA
J Magn Reson Imaging; 1995; 5(4):470-2. PubMed ID: 7549213
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy.
White GW; Gibby WA; Tweedle MF
Invest Radiol; 2006 Mar; 41(3):272-8. PubMed ID: 16481910
[TBL] [Abstract][Full Text] [Related]
10. Effect of the surface potential of the hemodialysis membrane and the electrical charge of the gadolinium contrast medium on dialyzability.
Okada S; Inoue K; Kijima T; Katagiri K; Kumazaki T
J Nippon Med Sch; 2003 Feb; 70(1):12-5. PubMed ID: 12646970
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging.
Schuhmann-Giampieri G; Frenzel T; Schmitt-Willich H
Arzneimittelforschung; 1993 Aug; 43(8):927-31. PubMed ID: 8216456
[TBL] [Abstract][Full Text] [Related]
12. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC
Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739
[TBL] [Abstract][Full Text] [Related]
13. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
[TBL] [Abstract][Full Text] [Related]
14. Contrast enhancement of the inner ear after intravenous administration of a standard or double dose of gadolinium contrast agents.
Suzuki H; Teranishi M; Sone M; Yamazaki M; Naganawa S; Nakashima T
Acta Otolaryngol; 2011 Oct; 131(10):1025-31. PubMed ID: 21732744
[TBL] [Abstract][Full Text] [Related]
15. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents.
Kimura J; Ishiguchi T; Matsuda J; Ohno R; Nakamura A; Kamei S; Ohno K; Kawamura T; Murata K
Radiat Med; 2005 Aug; 23(5):322-6. PubMed ID: 16342903
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic behavior of gadoteridol injection.
McLachlan SJ; Eaton S; De Simone DN
Invest Radiol; 1992 Aug; 27 Suppl 1():S12-5. PubMed ID: 1506147
[TBL] [Abstract][Full Text] [Related]
17. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability.
Tombach B; Bremer C; Reimer P; Matzkies F; Schaefer RM; Ebert W; Geens V; Eisele J; Heindel W
AJR Am J Roentgenol; 2002 Jan; 178(1):105-9. PubMed ID: 11756100
[TBL] [Abstract][Full Text] [Related]
18. Distribution and clearance of retained gadolinium in the brain: differences between linear and macrocyclic gadolinium based contrast agents in a mouse model.
Kartamihardja AA; Nakajima T; Kameo S; Koyama H; Tsushima Y
Br J Radiol; 2016 Oct; 89(1066):20160509. PubMed ID: 27459250
[TBL] [Abstract][Full Text] [Related]
19. Elimination of gadolinium-DTPA by peritoneal dialysis.
Dörsam J; Knopp MV; Schad L; Piesche S; Carl S; Oesingmann N
Nephrol Dial Transplant; 1995; 10(7):1228-30. PubMed ID: 7478129
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy.
Gibby WA; Gibby KA; Gibby WA
Invest Radiol; 2004 Mar; 39(3):138-42. PubMed ID: 15076005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
